SpiroTact®

Rapid Syphilis Screening

Syphilis continues to be a growing global health issue, with over 7 million new cases annually (WHO) The syphilis diagnostics market is projected to exceed $3 billion by 2030, driven by rising infection rates. This increases the need for affordable, accessible diagnostics.
New Syphilis cases 0 Million per year
Pexels Tima Miroshnichenko 5452221

Syphilis remains a major global health challenge

Current diagnostic methods for the detection of Syphilis can be slow, complex, and expensive. Traditional serological testing often fails to differentiate between past and active infections, leading to misdiagnosis and delayed treatment, particularly in resource-limited settings.

Early detection and treatment is crucial to prevent complications, reduce transmission, and with regards to congenital Syphilis protect maternal and infant health.

Our Solution

2026-03-26_DetactDiagnostics_CasperMaasImg2964_
SpiroTact®

Rapid, reliable Syphilis Detection

SpiroTact® is a rapid, user-friendly diagnostic test that directly detects active Treponema pallidum. Unlike, serological tests that could return positive results even in case of past infections, SpiroTact® is designed to detect active spirochete presence.

How SpiroTact® works

2026-03-26_DetactDiagnostics_CasperMaasImg3031_
Collect

No Sample Prep

Directly transfer sample to the VIPER® assay tube containing the SpiroTact® assay
2026-03-26_DetactDiagnostics_CasperMaasImg3004_
Read

Reader Agnostic

Place the VIPER® assay tube containing the sample, into the DeNIRO® mini Fluorometer (point-of-care) or plate reader (lab-based testing)
Roberto Sorin RS0 H PyByk Unsplash
Treat

Actionable Results

SpiroTact® is designed to provide actionable data within minutes which could enable health care professionals to start immediate targeted treatment

Potential benefits of SpiroTact® to healthcare providers

Early Intervention

SpiroTact® could enable prompt treatment to reduce transmission and complications

Fast Detection

SpiroTact® aims to Identify Syphilis infections in minutes, not hours

Accessible

Low cost and scalability, position SpiroTact® for adoption in centralized clinics, but also for global health initiatives in LMIC's

User friendly

Designed with minimal training required for healthcare workers
SpiroTact Pilot Study

Pilot Study, East London, South Africa

In April 2024 the Detact Team had the opportunity to travel to East London, South Africa, to the Foundation for Professional Development and conduct site visits at several STI clinics and primary healthcare facilities, as part of development project on a syphilis diagnostic tool called SpiroTact®

Our Point-of-Care NIR Fluorometer

2026-03-26_DetactDiagnostics_CasperMaasImg2926_

Breakthrough Technology – The VIPER® platform is being designed to detect active infections with accuracy and speed

VIPER® Technology

Other VIPER® Applications

Chronic PJI
RenoTact®
Rapid Detection of PD Peritonitis
Allergies
SynoTact®
Rapid Detection of Periprosthetic Joint Infections
Peritonitis
MycoTact®
Rapid Detection of Tuberculosis Infection
Tuberculosis
EnzoTact®
Preventing Milk Spoilage with Rapid Protease Detection

SpiroTact® is currently for research use only and is not for use in diagnostic procedures; the performance characteristics of this product have yet to be established